ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2023 after the market closes…Read More
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
